A previous phase 2 study of patients undergoing non-urgent PCI treated with SCH530348 plus aspirin and clopidogrel tended to reduce MACE without increased bleeding. This study evaluated the safety of SCH530348 in Japanese patients with NSTE ACS. Methods: Subjects (117), in whom PCI was planned, received standard-of-care (aspirin, ticlopidine, and heparin) and were randomized 4:1 to receive either SCH530348 (20 or 40 mg loading dose followed by 1 mg/d or 2.5 mg/d for 60 days) or placebo. The key safety endpoint was TIMI major and minor bleeding in the PCI cohort (n 92). The key exploratory efficacy endpoint was MACE and death within 60 days. Addition of SCH530348 to standard-of-care did not significantly increase the rate of TIMI major and minor bleeding (or non-TIMI bleeding) in the primary cohort. Results: Incidence (non-MACE) and discontinuation of AEs were similar across groups. PCI subjects treated with SCH530348 plus standard-of-care experienced a significant reduction in periprocedural MI compared with standard-of-care alone (16.9% vs 42.9%, respectively; p 0.013). There were no deaths or any other MACE. Conclusion: SCH530348 added to standard-of-care did not result in excess bleeding in Japanese subjects with NSTE ACS but significantly reduced the incidence of periprocedural MI in subjects undergoing urgent PCI. , 2010; 17:156-164. 
Introduction
The formation of platelet-rich thrombi in response to vascular injury (via plaque rupture) is the major pathologic event responsible for the clinical manifestations of non-ST-segment elevation acute coronary syndrome (NSTE ACS) 1, 2) . Pro-inflammatory cytokines and thrombogenic molecules (e.g., tissue endpoint of cardiovascular [CV] death, myocardial infarction [MI], or stroke) remained in both the aspirin plus clopidogrel (12.1%) and aspirin plus prasugrel (9.9%) treatment groups 7) . The risk for recurrent ischemic events can be attributed to the fact that conventional therapy with aspirin and P2Y12 ADP receptor antagonists does not inhibit the other platelet activation pathways, most notably thrombin-mediated platelet activation via the PAR-1 receptor 1) .
In addition, excess bleeding is observed with the combination of aspirin and P2Y12 ADP receptor antagonists 6, 7, 9) , since these platelet activation pathways are involved not only in pathologic thrombosis but also in protective hemostasis 1) . A higher incidence of hepatic side effects with the use of thienopyridine P2Y12 ADP receptor antagonists in Japanese patients 10) , due to race-specific haplotype 11) , also limits the use of these P2Y12 ADP receptor antagonists in Japan. Anti-GP b/ a agents, which can inhibit platelet aggregation and reduce thrombotic vascular events after percutaneous coronary intervention (PCI), were proven to induce excess bleeding in Japanese patients and thus have not been approved in Japan 12) . Therefore, new therapies to reduce thrombotic vascular events without increased bleeding liability are urgently needed in Japan.
The most potent platelet activation pathway contributing to thrombosis involves the binding of thrombin to protease-activated receptor (PAR)-1 13) . Importantly, thrombin-mediated cleavage of fibrinogen into fibrin may be more critical for hemostasis than platelet activation induced by thrombin through PAR-1 13) . Thrombin plays a key role in the positive feedback between activation of the platelet and coagulation cascades 14) . Preclinical studies have shown that PAR-1 antagonism inhibits thrombin-stimulated platelet aggregation and pathogenic thrombus growth without prolonging bleeding time 15) , supporting the concept that the PAR-1 pathway may not have a significant role in hemostasis. These observations suggest that inhibition of the PAR-1 pathway may reduce thrombosis and resulting ischemic events without increasing the risk of bleeding.
SCH530348 is a novel, potent, orally bioavailable thrombin receptor antagonist (TRA) selective for PAR-1 16) . A recent phase 2 safety trial in 1030 subjects scheduled for non-urgent PCI demonstrated that treatment with SCH530348, in addition to aspirin and clopidogrel, was not associated with increased rates of TIMI major or minor bleeding, while demonstrating a non-statistically significant trend toward a reduced incidence of ischemic events, specifically periprocedural MI 17) .
Clinical studies with SCH530348 have confirmed similar pharmacokinetics and pharmacodynamics (inhibition of platelet aggregation) in Caucasian and Japanese subjects 18, 19) . The doses in the present study were chosen based on the pharmacokinetics and pharmacodynamics of SCH530348 observed in phase 1 studies 18) , and to overlap with the recent ex-Japanese phase 2 study 17) . Single oral "loading doses" of SCH530348 20 mg and 40 mg achieved the predefined goals of ≥ 80% platelet aggregation inhibition at 1 hour, as did the "maintenance dose" of 2.5 mg/day with ≥ 80% platelet aggregation inhibition in most subjects as early as 7 days in previous studies 18) . The present study was designed to evaluate the safety and efficacy of SCH530348 in Japanese subjects with NSTE ACS receiving standard-of-care therapy at the time of this trial (aspirin, ticlopidine, and heparin), and planned for PCI.
Methods

Subjects
Subjects were men and women aged ≥ 18 years with a history of ischemic chest discomfort of ≥ 10 minutes duration within 24 hours prior to enrollment. Subjects who had either CK-MB or troponin-I above the upper limit of normal or electrocardiogram changes (new ST segment depression of ≥ 1 mm or transient ST segment elevation in at least 2 contiguous leads), and in whom PCI was planned, were eligible for enrollment. Written informed consent was obtained from all subjects before study enrollment. Major exclusion criteria included: pregnancy, serious illness, use of any investigational drug within 30 days, history of a bleeding diathesis, severe hypertension, major surgery within 2 weeks, platelet count 100,000/mm 3 , and impaired renal and/or hepatic function.
Study Design
This was a multicenter, randomized, doubleblind, placebo-controlled, sequential and parallel group trial conducted in Japan. The study protocol was approved by the institutional review board of the participating sites. Subjects with NSTE ACS receiving standard-of-care therapy at the stant of this study (aspirin, ticlopidine, and heparin) were randomized to receive a loading dose of SCH530348 (20 or 40 mg) or placebo no less than 1 hour prior to catheterization, and if PCI was commenced, daily oral maintenance dosing with SCH530348 (1 or 2.5 mg) or placebo for 59 additional days. These patients were defined as the primary (PCI) cohort. Non-PCI subjects did not receive any maintenance dose and were defined as the secondary (non-PCI) cohort. Subjects in the secondary cohort were subsequently managed medically or underwent coronary artery bypass graft surgery.
Clinical Safety and Efficacy Endpoints
The key safety endpoint was bleeding classified according to the TIMI criteria (major, minor, non-TIMI). TIMI major bleeding was defined as intracranial hemorrhage or clinically significant overt signs of bleeding associated with a decrease in hemoglobin concentration of 5 g/dL (or decrease in hematocrit 15%). TIMI minor bleeding was defined as clinically overt signs of bleeding (including via imaging) associated with a decrease in hemoglobin concentration of 3 to ≤ 5 g/dL (hematocrit 9% to ≤ 15%) that did not otherwise meet the criteria for major bleeding. Changes in hemoglobin or hematocrit were corrected to account for any transfused blood. Clinically important bleeding was defined as the composite incidence of intracranial bleeding and bleeding requiring blood transfusion and re-hospitalization.
The exploratory efficacy endpoints included all-cause death and MACE (non-fatal MI, non-fatal stroke, hospitalization for recurrent ischemia, or urgent coronary revascularization). Periprocedural MI was defined as an elevation of CK-MB or troponin-I above 3 times the upper limit of normal, with at least a 50% increase from the value prior to the procedure. Samples for determination of CK-MB or troponin-I in the primary (PCI) cohort were collected at baseline (prior to study drug administration) and at 8, 16, and 24 hours after PCI. Sampling was repeated following a suspected episode of ischemia during hospitalization.
Adverse Events and Laboratory Evaluations
Subjects were monitored for AEs, and underwent physical examinations, ECGs, and laboratory tests (complete blood count and platelet count, PT and aPTT, biochemistry panel, urinalysis, fecal occult blood) at predefined time points.
Platelet Function
Two selected sites included testing to assess inhibition of platelet aggregation induced by TRAP and other agonists (e.g., ADP, arachidonic acid, and collagen).
Statistical Methods
Numerical data are expressed as the mean SD unless otherwise stated. The differences in incidence between treatment groups for AEs, bleeding events (TIMI major and minor bleeding, non-TIMI bleeding, clinically significant bleeding, and any bleeding), and MACE with corresponding 95% CI were calculated. The number of subjects in this study was decided based on subject numbers from phase 2 studies of similar drugs conducted before. Chi-square test was used for categorical endpoints and p value 0.05 was considered statistically significant. 
Results
Patient Characteristics
A total of 120 Japanese subjects were enrolled, and 117 were randomized to SCH530348 or placebo ( Fig. 1) . Of the 117 randomized subjects, 92 underwent PCI and were defined as the primary (PCI) cohort, whereas the remaining 25 subjects constituted the secondary (non-PCI) cohort.
Demographic and baseline characteristics of subjects in the primary (PCI) cohort randomized to receive placebo and SCH530348 were similar ( Table 1) . Approximately 79% of subjects underwent PCI, and 95% of these received intracoronary stent placement. The vast majority of patients in both the placebo and SCH530348 groups were men, and approximately half of the patients in each treatment arm were 65 years of age or older. All primary (PCI) cohort subjects received the protocol-specified regimens of aspirin, ticlopidine, and heparin.
Primary (PCI) Cohort
Bleeding
The incidence of combined TIMI major plus minor bleeding during the 60-day treatment phase was 14% in the SCH530348-treated patients and 10% in placebo-treated patients (point estimate of the difference: 4.6% [95% CI: 10.4 to 19.5]; Table 2 ). Bleeding of any severity was reported in 61% of patients treated with SCH530348 and 52% of those receiving placebo (point estimate of the difference: 8.2% [95% CI: 16.0 to 32.4]; Table 2 ). The rates of non-TIMI bleeding events in the SCH530348 and placebo groups were also comparable (55% and 52%, respectively; Table 2 ). Clinically important bleeding events, including bleeding requiring blood transfusion and rehospitalization, during the treatment phase were reported in 5 (7%) subjects treated with SCH530348 and none of those treated with placebo ( Table 2) .
Ischemic Events
During the 60-day treatment phase, primary (PCI) cohort subjects treated with SCH530348 plus standard-of-care therapy had significantly fewer MIs, as defined in the Methods section, when compared with subjects receiving the standard-of-care therapy alone (16.9% vs 42.9%, respectively; p 0.013; Fig. 2) . The rates of non-fatal MI in the SCH530348 20 mg and 40 mg loading-dose groups were comparable. The majority of MIs were asymptomatic elevations of CK-MB or troponin-I and occurred during the periprocedural period shortly after PCI. None of the primary (PCI) cohort subjects in any of the treatment groups died or experienced other MACE (non-fatal stroke, recurrent ischemia with hospitalization, or urgent coronary revascularization).
Adverse Events
The rates of serious AEs and discontinuations due to AEs in the primary (PCI) cohort during the 60-day treatment phase in the SCH530348 and placebo groups were similar ( Table 3) . The rates of serious AEs were 8% (6/71) with SCH530348 and 14% (3/21) with placebo. Discontinuation because of an AE occurred in 20% (14/71) of SCH530348-treated subjects and in 38% (8/21) of placebo-treated subjects. The rates of AEs during the 60-day treatment phase were also similar between the placebo and SCH530348 groups ( Table 3) . Although epistaxis and subcutaneous hemorrhage occurred at a higher frequency with SCH530348 compared with placebo, these events were considered to be unrelated to treatment by the treating physicians, and no subject discontinued the study due to these events. Two subjects experienced TIMI major bleeding during the treatment phase: cardiac tamponade secondary to ventricular rupture, puncture site hemorrhage, and blood in the urine in a patient who received 20 mg SCH530348, and decreased hemoglobin in a patient who received 40 mg SCH530348. Results of laboratory tests and vital signs were similar between SCH530348 and placebo groups.
Secondary (Non-PCI) Cohort
In the secondary (non-PCI) cohort, only 2 subjects received placebo, whereas 23 subjects received the loading dose of SCH530348. Therefore, meaningful comparisons across the groups could not be made.
Among the 23 subjects treated with SCH530348, 3 had TIMI major bleeding (2 associated with CABG but considered unlikely related to the study drug), and no TIMI minor bleeding was reported ( Table 4) . Additionally, serious AEs during the protocol-specified treatment phase were reported in 2 (9%) subjects treated with SCH530348 (cellulitis in a 69-year-old woman, and a rib fracture and traumatic subarachnoid hemorrhage in a 73-year-old woman).
Discussion
This is the first study designed to assess the safety of SCH530348, a novel, oral thrombin receptor antagonist (TRA) selective for PAR-1, in Japanese patients with acute atherothrombotic disease receiving standard-of-care therapy (aspirin, ticlopidine, and heparin). The overall safety profile of SCH530348 in this study was favorable. The incidence of TIMI major and minor bleeding and non-TIMI bleeding events in the primary (PCI) cohort during the 60-day treatment period was comparable between the SCH530348 and placebo groups. Whereas clinically important bleeding was more common among subjects treated with SCH530348 overall, none of the subjects receiving the higher 2.5 mg dose experienced clinically important bleeding. Incidence of serious AEs and discontinuations due to AEs in the primary (PCI) cohort in subjects receiving SCH530348 and those receiving 3 (18) placebo was similar. In addition, the incidence of AEs was comparable across the treatment arms.
The addition of SCH530348 to standard therapy (aspirin, ticlopidine, and heparin) was associated with a significant relative reduction (61%, p 0.013) in the incidence of non-fatal periprocedural MI vs standard therapy alone in the primary (PCI) cohort. The majority of MIs were asymptomatic periprocedural elevations of cardiac enzymes, and their prevention with SCH530348 suggests that this agent has rapid therapeutic antithrombotic action. No other ischemic events were reported in any of the treatment groups during the protocol-specified 60-day treatment phase.
In this study, SCH530348 in Japanese patients undergoing urgent PCI was not associated with significantly increased bleeding risk, while showing a reduction in ischemic events. These results are similar to that reported in a larger phase 2 TRA-PCI trial in non-Japanese patients undergoing non-urgent PCI 17) . Taken together, these findings support future clinical development of SCH530348.
Similar to the preliminary clinical evidence discussed above, which suggests that PAR-1 inhibition may not be associated with increased bleeding risk, the absence of an adverse impact on bleeding parameters has also been reported in preclinical studies with SCH530348 20) and other PAR-1 antagonists 15, 21) . Additionally, genetic inactivation of the principal thrombin receptor on mouse platelets (PAR-4, which corresponds to PAR-1 on human platelets) does not result in spontaneous bleeding 22) . These data collectively suggest that inhibition/inactivation of the principal platelet thrombin receptor pathway may not increase the risk for bleeding complications.
Several factors may help explain the observed lack of incremental bleeding risk associated with inhibition/ inactivation of the principal platelet receptor for thrombin. First, genetic inactivation of the principal thrombin receptor on mouse platelets does not interfere with either the initial platelet deposition or fibrin generation required for normal hemostasis and healing in response to vascular injury 22) . Additionally, PAR-1 inhibition does not interfere with platelet binding to and activation by collagen 15, 23) , which is important for normal hemostasis. Conversely, increased risk of bleeding with P2Y12 ADP receptor antagonists may be related to the fact that these agents inhibit platelet activation by collagen 24) . The same is true for anti-GP b/ a agents. Finally, it is possible that PAR-4, the secondary thrombin receptor on human platelets, may also contribute to normal hemostasis, particularly in the presence of PAR-1 receptor inhibition.
The major limitations of this study include the small sample size of each treatment group, especially considering that both loading doses and maintenance doses were being studied, and the relatively short duration of treatment (2 months). Also, although pharmacodynamic (platelet aggregation inhibition) assessments were planned and performed in select centers, there were too few patients to analyze, and this was not a major focus of the study. In summary, cumulative preclinical and clinical evidence, including the results of this phase 2 trial in Japanese patients undergoing urgent PCI, suggests that the use of the PAR-1 antagonist SCH530348 in combination with aspirin and a P2Y12 ADP receptor antagonist may not be associated with increased risk of bleeding while potentially reducing the incidence of recurrent ischemic events, specifically MI, in patients at risk for thrombotic events. Two large, ongoing, multinational phase 3 trials, including Japanese sites, have been designed to provide adequate statistical power to rigorously evaluate the clinical efficacy and safety of SCH530348 in combination with standardof-care therapy in patients presenting with NSTE ACS (TRA • CER, N 10,000; ClinicalTrials.gov identifier: NCT00527943) and in those with a prior history of coronary artery, cerebrovascular, or peripheral artery disease (TRA 2P-TIMI 50, N 25,000; Clini-calTrials. gov identifier: NCT00526474).
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